Enzyre, which is developing breakthrough ambulant diagnostic technology for coagulation testing, announces today the appointment of Dirk Pollet as Chief Executive Officer. It also announces the award of €2M European Fund for Regional Development (EFRO) grant and closing of a successful seed funding round which enables Enzyre to accelerate the development of its unique Hemophilia Biochip technology.
Enzyre’s platform technology requires just a small volume of blood and is able to measure up to twelve reactions simultaneously with high sensitivity and specificity, that can be carried out at home, on the road or in a critical care setting, without any laboratory infrastructure. This has the potential for better disease management and to improve the lives of patients living with chronic conditions whilst reducing healthcare costs.
Enzyre, a spin-out from Radboud University Medical Center in The Netherlands, was set up by Guido Maertens and Waander van Heerde, to develop innovative point of care (POC) devices to measure biomarkers in complex solutions. POC diagnostic tools are crucial for cost reduction and offer the flexibility to allow disease management to move to personalized medicine in the home or critical care setting. Enzyre’s POC device aims to revolutionize the understanding and diagnosis of multiple thrombotic and hemostatic disorders by providing a real-time picture of a patient’s blood coagulation status. The total market size for hemophilia is estimated at €12B per year. The €2M EFRO grant and the seed financing will enable Enzyre to further develop its Hemophilia Biochip and bring its first product to market.
Tolleiv Trimborn, Chairman of Enzyre’s Supervisory Board, said: “We are delighted to have Dirk Pollet join the team as CEO. He brings a successful track record and 20 years of experience in the successful development and commercialization of in vitro diagnostics (IVD) and deal-making. We would also like to thank Guido Maertens for his commitment and hard work as founding CEO and we are fully convinced that he will continue to contribute to the success of Enzyre as he embraces his new task as CFO.”